TB-500 FAQ: Questions from the Research Community

Definitions and Basics

What is TB-500?

TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of Thymosin Beta-4, an endogenous signaling protein studied for its role in actin regulation, cell migration, and tissue repair in preclinical models. The acetylated N-terminus distinguishes it from the native TB4 sequence. Molecular weight: 887 daltons.

What does TB-500 stand for?

TB-500 refers to Thymosin Beta-500 — a naming convention used in research and anti-doping contexts for the synthetic heptapeptide fragment corresponding to residues 17–23 of Thymosin Beta-4. The '500' designation appeared in early peptide synthesis literature to distinguish the fragment from the parent protein. In current research it is more precisely labeled Ac-LKKTETQ or N-acetyl-LKKTETQ.

What is the relationship between TB-500 and Thymosin Beta-4?

Thymosin Beta-4 (Tβ4) is the full endogenous 43-amino-acid protein. TB-500 is a synthetic 7-amino-acid fragment corresponding to its actin-binding region (residues 17–23). TB-500 preserves the G-actin sequestration activity of Tβ4 but may not replicate all of the parent protein's biological effects. The full protein has been studied in human clinical trials; the fragment has not. The two are mechanistically related but not pharmacokinetically equivalent.

Is TB-500 a steroid?

No. TB-500 is a synthetic peptide — a short amino acid chain. It is structurally and mechanistically distinct from anabolic steroids, which are lipid-soluble cholesterol derivatives acting on nuclear receptors. TB-500 acts on G-actin cytoskeletal dynamics and VEGFR2-mediated cell-surface signaling. WADA classifies it under S2 (Peptide Hormones, Growth Factors, Related Substances) — the peptide category.

What peptides does TB-500 combine with in research stacks?

TB-500 is most commonly co-discussed with BPC-157 in what researchers and community literature label the 'Wolverine stack' — hypothesized to combine BPC-157's GI-protective and tendon-fibroblast-specific effects with TB-500's systemic angiogenic and anti-fibrotic properties. No published peer-reviewed study has tested the two together in a controlled design. All combination claims derive from extrapolation from each compound's independent preclinical literature.

Mechanism and Effects

How does TB-500 work?

TB-500 binds monomeric G-actin in a 1:1 stoichiometric ratio, sequestering it and modulating cytoskeletal dynamics. This promotes cell motility and migration, upregulates VEGFR2-mediated angiogenesis, reduces inflammation via microRNA-146a upregulation and macrophage M2 polarization, and activates ILK/Akt survival signaling in cardiomyocytes. Multiple downstream effects emerge from that single actin-binding interaction.

What is TB-500 used for in research?

Preclinical research has examined TB-500 and Thymosin Beta-4 in models of wound closure ^[1][2], tendon and ligament repair ^[3], cardiac tissue regeneration post-infarction ^[4][5], hair follicle stem cell activation ^[6], traumatic brain injury ^[8], axon regeneration ^[19], and liver inflammation and fibrosis ^[14][21]. No FDA-approved human indication exists for the compound.

What is the benefit of BPC-157 and TB-500 together?

Researchers have studied BPC-157 and TB-500 as mechanistically complementary: BPC-157 is associated with GI protection, tendon fibroblast activity, and local angiogenesis; TB-500 is studied for systemic actin-cytoskeletal modulation, VEGFR2-mediated angiogenesis, and anti-fibrotic effects. The hypothesized complementarity is mechanistically plausible based on each compound's independent preclinical record. Combined protocols appear in anecdotal literature; head-to-head human trials are absent.

Does TB-500 increase hair growth?

Thymosin Beta-4 activated quiescent hair follicle stem cells in the bulge region at nanomolar concentrations in rodent vibrissal follicle models, stimulating keratinocyte migration, differentiation, and MMP-2 secretion ^[6]. TB-500 (the synthetic 7-residue fragment) has not been independently validated for hair growth in peer-reviewed trials. The hair follicle findings come from full-length Tβ4 studies.

Is TB-500 good for the heart?

Thymosin Beta-4 has been studied in murine myocardial infarction models, where ILK/Akt pathway activation promoted cardiomyocyte survival ^[4] and AAV-delivered Tβ4 reduced cardiac inflammation and fibrosis via mitophagy promotion ^[5]. These are preclinical findings in mice. No human cardiac efficacy trial for Tβ4 or TB-500 has been published in peer-reviewed literature.

Does TB-500 help the heart?

Preclinical cardiac models (primarily murine) show Thymosin Beta-4 promotes angiogenesis and reduces cardiomyocyte apoptosis post-injury via ILK/Akt signaling. Two independent murine MI studies confirmed cardiac protective effects ^[4][5]. Human cardiac efficacy evidence is absent from the published literature.

Does TB-500 only work for physical injury or can it help with systemic inflammation?

The research literature extends beyond musculoskeletal injury. Tβ4 has been studied for anti-inflammatory effects in cardiac tissue ^[5], liver fibrosis ^[14], NAFLD ^[21], and traumatic brain injury ^[8]. The mechanism — macrophage M2 polarization, MAPK/NF-κB pathway suppression, miR-146a upregulation — is systemic rather than tissue-specific. Whether the 7-residue TB-500 fragment reproduces systemic anti-inflammatory effects observed with the full Tβ4 protein has not been validated in published studies.

Dosage and Administration

How much TB-500 should I take?

This reading room describes research quantities used in published animal studies — not clinical recommendations. Preclinical animal studies use weight-based dosing ranging from 1 µg local (rat ligament) ^[3] to 12 mg/kg/day IP (mouse liver model) ^[21]. Extrapolation to humans is not validated. This is research context only.

Can TB-500 be taken every day?

Preclinical protocols vary. Some animal studies use daily administration (the NAFLD model at 12 mg/kg/day ^[21]); others use 2–3× weekly (Spurney et al. 2010, twice weekly × 6 months in mdx mice ^[16]). The human Phase I IV trial used daily dosing over 14 days for the repeat-dose cohort ^[9]. No validated human dosing schedule exists for musculoskeletal or systemic indications.

How quickly does TB-500 work?

Animal studies report measurable tissue-repair markers within days to weeks, depending on the model: wound re-epithelialization improvements were measured at day 4 and day 7 ^[2]; ligament histological improvements at 4 weeks ^[3]; neurological TBI improvements at 35 days ^[8]. No validated human onset data is available.

How long does TB-500 stay in your system?

No peer-reviewed human pharmacokinetic data for TB-500 (Ac-LKKTETQ) specifically. For full-length Tβ4, human Phase I IV data confirmed dose-proportional pharmacokinetics with no accumulation on 14-day repeat dosing ^[9][10]. Specific half-life values were not published in available abstracts. Detection windows in anti-doping contexts have been partially characterized in equine samples by LC-MS/MS ^[12], but human detection window data has not been published in peer-reviewed form.

Can TB-500 be taken orally?

Most preclinical research administers TB-500/Tβ4 via subcutaneous, intraperitoneal, local/intralesional, or intravenous routes. Oral peptide delivery faces proteolytic degradation in the GI tract. Oral bioavailability of TB-500 has not been established in peer-reviewed studies in any species. Community-context oral administration anecdotes exist but are not supported by published pharmacokinetic evidence.

Where to inject TB-500?

Animal studies employ subcutaneous and intramuscular injection routes in rodent models. Intravenous and intraperitoneal routes appear in some rodent and human Phase I protocols. The anti-doping equine literature identifies subcutaneous as the route for which detection methodology was validated ^[12]. Injection-site preference in community research contexts is anecdotal and not addressed in the clinical literature.

How to reconstitute TB-500?

Research laboratory preparations of Tβ4 and TB-500 for animal studies use bacteriostatic water or sterile saline as the diluent for injectable preparations. Stability and concentration vary by study protocol; no standardized clinical reconstitution guideline exists. This reflects research practice, not a preparation instruction.

Do you NEED to keep dosing TB-500 to maintain results?

The published literature does not address maintenance dosing in the context of this question. The chronic mdx mouse study (Spurney 2010) administered twice-weekly IP for 6 months and showed increased regenerating fiber count; no follow-up data characterized what happened post-cessation ^[16]. For wound healing studies, treatment periods were short-course and endpoint measurement was at defined time points. Maintenance dosing claims in community contexts are not derived from controlled clinical evidence.

Safety and Regulatory

What are the side effects of TB-500?

In animal studies, TB-500 and Tβ4 are generally well-tolerated. Human Phase I trials of full-length Tβ4 reported infrequent, mild-to-moderate adverse events with no dose-limiting toxicities at IV doses up to 1260 mg in 40 volunteers ^[9][10]. Anecdotal adverse events in human community contexts include injection-site reactions, temporary fatigue, and mild dizziness. Long-term human safety data for the synthetic TB-500 fragment does not exist in peer-reviewed form.

What are the side effects of TB-500 combined with BPC-157?

No formal human safety studies exist for the TB-500 + BPC-157 combination, and no controlled animal study of the combination has been published in indexed literature. Anecdotal reports cite similar individual adverse events — injection-site reactions and fatigue — without documented additive toxicity in the available literature. The combination data gap is real.

What are the bad side effects of taking peptides?

Research peptides carry risks including injection-site reactions, immune responses to exogenous protein sequences, unknown long-term effects, and purity concerns from unregulated commercial sources. TB-500 has not been approved by the FDA for human use. Any injectable compound used outside a controlled medical setting carries inherent infection risk from non-sterile technique.

Who should avoid peptides?

Clinical commentary notes that individuals with active malignancy, autoimmune conditions, or during pregnancy warrant particular caution — Tβ4's pro-angiogenic and cell-migration-promoting mechanisms are theoretically relevant in contexts where those processes are already dysregulated. These are not formal contraindications established by clinical trial data; they are mechanistic extrapolations from the preclinical literature. This site does not provide clinical guidance.

Is TB-500 safe?

Animal studies report favorable tolerability. Human safety data is limited to short-term Phase I trials of the full-length Tβ4 protein, which showed mostly mild, transient adverse events at IV doses up to 1260 mg in 40-person cohorts ^[9][10]. TB-500 (the 7-residue synthetic fragment) has no published human safety trial. Long-term effects are unknown. The data supports 'apparently tolerated in controlled animal studies and in human Phase I trials of the full protein' — not 'proven safe.'

Is TB-500 FDA approved?

TB-500 is not FDA-approved for any human indication. It is studied as a research compound only. Full-length recombinant Tβ4 has been studied in Phase I and Phase 2 human trials with favorable tolerability in specific contexts ^[9][10], but no FDA-approved product containing TB-500 or Tβ4 for systemic human use exists as of 2025. TB-500 is not a controlled substance under the Controlled Substances Act.